A recent study explored the potential of DMT, being an endogenous agonist of S1R, to ameliorate these pathological hallmarks in a transgenic (TG) AD mouse model (3×TG-AD) [16]. This evidence concerns the gene TMBIM4 and Alzheimer disease.